Graphite Bio is a next-generation gene-editing company focused on the development of potentially curative therapies for patients suffering from serious diseases. The company’s targeted gene integration platform harnesses the cellular process of homology directed repair (HDR) to efficiently repair genetic defects at their source, deliver genetic cargo with precision, and engineer new cellular effector functions. Graphite Bio is leveraging its differentiated platform, initially focused on ex vivo engineering of hematopoietic stem cells, to advance a portfolio of transformative treatments with the potential for saving and dramatically improving patients’ lives. Graphite Bio’s approach is based on the extensive work and expertise of our academic co-founders Matthew Porteus M.D., Ph.D. and Maria Grazia Roncarolo, M.D., Ph.D. at the Center for Definitive and Curative Medicine (CDCM) at Stanford University. NASDAQ: GRPH